Harmony Biosciences Holdings, Inc. Q2 2026 Earnings Recap

Investor optimism was driven by better-than-expected commercial execution, with WAKIX revenue surging 30% year-over-year and a reaffirmed full-year revenue guidance of $1 billion to $1.04 billion. Encouraging early data from the BP-205 orexin-2 agonist pipeline also added confidence.

Key Takeaways

• WAKIX net revenue hit a record $261.3 million in Q2, up 30% year-over-year and 21% sequentially after seasonal headwinds in Q1.
• Full-year 2026 net revenue guidance reiterated at $1 billion to $1.04 billion, consistent with previous outlook.
• Promising Phase I single ascending dose data for BP-205 support its potential as a best-in-class orexin-2 receptor agonist with once-daily dosing potential.
• Multiple upcoming data catalysts for BP-205 expected over the next six months, including Phase II trials starting mid-2027.
• Strong balance sheet with approximately $963 million in cash enables continued investment in pipeline and strategic business development opportunities.